In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Can Electroporation Revive Gene Therapy?

Executive Summary

As regulators increase their scrutiny of viral vectors for gene therapy and set the bars for safety ever higher, some industry observers have begun questioning whether gene therapy will ever become a commercial reality. The difficulties in the field may turn out to be a life-saver for MaxCyte Inc. Its managers think their flow electroporation technology could be a platform for transforming patients' cells and getting them to produce a desired protein--without viruses, and the risks they bring.

You may also be interested in...

Vical Leaves Gene Therapy for Vaccines

Is gene therapy ever going to become a routine, reliable method of disease treatment? It appears that the odds of success in anything like the near term are slimming. Now one of the first companies to get involved in gene therapy is finally giving up on it: San Diego-based Vical Inc., founded in 1987, recently announced its intention to use its naked DNA technology to develop a vaccine for cytomegalovirus (CMV).

TheraMed Inc.

To carry on work focusing on the oxygen-delivering capacity of red blood cells, EntreMed Inc, (best known for its anti-angiogenic molecules) created spin-off TheraMed Inc. TheraMed has developed a prototype device and is experimenting with different sorts of reagents, which it believes will enable the three basic sorts of blood cells--platelets, red cells and white blood cells--to be transformed into delivery vehicles for oxygen, drugs, and genes.

Regeneron’s COVID-19 Antibody Cocktail Shows Early Promise, But Does It Merit An EUA?

Data from the first 275 patients in the trial are promising, but outside experts say they are wary of another hasty Emergency Use Authorization.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts